thiazolidinediones (TZDs)

Treatment Options for a Young, Newly Diagnosed Patient with a High BMI

Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD

Listen to the podcast and/or read the transcript.

Who is the Right Patient for SGLT-2 Inhibitors?

Dr. Leahy’s comments are right-on target. Some further observations by another endocrinologist who can’t determine who the best patient for this new class of drugs will be:
1.     The advisory committee had problems with the bump in LDL-cholesterol. True, this is a surrogate, not a true “outcome” that will be determined in the CANVAS study. But do you recall the last time we had this debate with a diabetes drug?